Psyence (PSYG) is a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well‑being. We have a focus on these conditions in the context of palliative care. Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com
External link for Psyence Group
Follow the #Psyence
Growing our Multi-Asset Biotech Company: Learn how Psyence Biomedical Ltd BioMed is one of the few vertically integrated biopharma companies with a focus on regulated psychedelics and how our expertise in clinical research, scalable production, and global supply, drive value. https://lnkd.in/efc8pmFc
Follow the #Psyence
CPCR Associate Center Director Albert Garcia-Romeu, PhD was interviewed on Texas Public Radio last week. He discusses how psychedelic research can be supported today. https://lnkd.in/e66T2sdZ
As we welcome Johns Hopkins Center for Psychedelic and Consciousness Research founding member Professor Albert Garcia-Romeu, PhD as chair of our new Scientific Advisory Board, and Professor Dan Stein, psychiatrist, and world authority on Adjustment Disorder, we also welcome the Psyence Biomedical Ltd presence on X (@PsyenceBiomed) where we share updates, breakthroughs, and deepen the conversation about Palliative Care and FDA-regulated psychedelic medicine for oncology patients.
Follow the #Psyence
Join Psyence Biomedical Ltd for key updates on clinical research, our new Scientific Advisory Board, and the future of psychedelic therapeutics. Date: Thursday, April 10, 2025 Time: 12:00 PM EDT Register here: https://lnkd.in/eZHtpixB for an Ask Us Anything conversation and live Q&A session with the Psyence Biomedical Ltd executive team: Dr. Neil Maresky, CEO, Dr. Clive Ward-Able Medical Director, and Warwick Corden-Lloyd, CFO.
Follow the #Psyence
Psyence Biomedical Ltd emerges from stealth to announce ALL STAR team of scientific advisors as Professor Dan Stein MD joins Yale School of Medicine's Dr. Seth Feuerstein MD, and Johns Hopkins Center for Psychedelic and Consciousness Research Associate Director Professor Albert Garcia-Romeu, PhD https://lnkd.in/eS5uW_Bg
Follow the #Psyence
Welcome Professor Dan Stein MD https://lnkd.in/erP8FcjC
Follow the #Psyence
Psychedelic Invest - Insights and Analyses on Psychedelics has shared the news that Professor Albert Garcia-Romeu, PhD of Johns Hopkins Center for Psychedelic and Consciousness Research has joined Psyence Biomedical Ltd as chair of its Scientific Advisory Board. https://lnkd.in/e7sYpFZv
Follow the #Psyence
Thank you BioSpace for the warm welcome to Professor Albert Garcia-Romeu, PhD of Johns Hopkins Center for Psychedelic and Consciousness Research as he joins Psyence Biomedical Ltd as chair of its Scientific Advisory Board! https://lnkd.in/ecKTpjha
Psyence Group reposted this
Throwback Thursday to this time last year when Psyence Biomedical Ltd arrived on the Nasdaq. This year: we welcome Dr. Albert Garcia-Romeu, PhD, of the Johns Hopkins Center for Psychedelic and Consciousness Research as he joins Psyence Biomedical Ltd as chair of its Scientific Advisory Board.
Working to bring FDA-approved nature-derived (non-synthetic) #psilocybin for an oncology-related indication in the context of Palliative Care, Psyence Biomedical Ltd is patient-centered, evidence-based, and physician-led by CEO Dr. Neil Maresky: News from Benzinga's psychedelic sector reporter Lara Goldstein on Psyence Biomedical Ltd's arrival on Nasdaq + Clinical Trials.
Welcome to Dr. Albert Garcia-Romeu, PhD, Associate Professor, Johns Hopkins Center for Psychedelic and Consciousness Research who joins Psyence Biomedical Ltd as chair of its Scientific Advisory Board.
